Gong Shunyou, Osei Ebenezer S, Kaplan David, Chen Youhai H, Meyerson Howard
Department of Pathology, University Hospitals Case Medical Center, Case Western Reserve University Cleveland 44106, Ohio, USA ; Department of Pathology and Laboratory Medicine, University of Pennsylvania Philadelphia 19104, PA, USA.
Department of Pathology, University Hospitals Case Medical Center, Case Western Reserve University Cleveland 44106, Ohio, USA.
Int J Clin Exp Pathol. 2015 Feb 1;8(2):1613-21. eCollection 2015.
CD317 was first identified as a multiple myeloma-associated antigen. Here we report the expression of CD317 in normal B cells and B-cell malignancies. In normal bone marrow, CD317 demonstrates a biphasic expression pattern, with higher expression on stage 1 and stage 3 hematogones, but not on stage 2 hematogones. CD317 is over-expressed in B-cell chronic lymphocytic leukemia, and appears associated with negative CD38 expression. Moreover, CD317 is barely detectable in B-cell acute lymphoblastic leukemia. Our results suggest that CD317 expression might be of prognostic significance for B-CLL, and CD317 could be used as a new marker for minimal residual disease detection in B-ALL.
CD317最初被鉴定为一种与多发性骨髓瘤相关的抗原。在此我们报告CD317在正常B细胞和B细胞恶性肿瘤中的表达情况。在正常骨髓中，CD317呈现双相表达模式，在第1阶段和第3阶段的造血细胞中表达较高，而在第2阶段的造血细胞中不表达。CD317在B细胞慢性淋巴细胞白血病中过度表达，并且似乎与CD38阴性表达相关。此外，在B细胞急性淋巴细胞白血病中几乎检测不到CD317。我们的结果表明，CD317表达可能对B细胞慢性淋巴细胞白血病具有预后意义，并且CD317可作为B细胞急性淋巴细胞白血病微小残留病检测的新标志物。
